A minimum of two years of undertreated primary hypothyroidism, as a result of drug-induced malabsorption of l-thyroxine, may have metabolic and cardiovascular consequences
Objective: Cross-sectional studies have reported that TSH above or close to the upper normal limit correlates with unfavorable metabolic and cardiovascular outcomes. Certain medications impair intestinal absorption of levothyroxine (L-T4), resulting in undertreated hypothyroidism (viz. failure of se...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-06-01
|
Series: | Journal of Clinical & Translational Endocrinology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2214623719300237 |
id |
doaj-3eb10e07ba0a47108734329646cfd1bf |
---|---|
record_format |
Article |
spelling |
doaj-3eb10e07ba0a47108734329646cfd1bf2020-11-24T23:55:26ZengElsevierJournal of Clinical & Translational Endocrinology2214-62372019-06-0116A minimum of two years of undertreated primary hypothyroidism, as a result of drug-induced malabsorption of l-thyroxine, may have metabolic and cardiovascular consequencesSalvatore Benvenga0Rachele Pantano1Giovanna Saraceno2Luigi Lipari3Antonio Alibrando4Santi Inferrera5Giuseppe Pantano6Giuseppe Simone7Sebastiano Tamà8Riccardo Scoglio9Maria Giovanna Ursino10Carmen Simone11Antonino Catalano12Umberto Alecci13Dipartimento di Medicina Clinica e Sperimentale, Università di Messina, Messina, Italy; Programma Interdipartimentale di Endocrinologia Molecolare Clinica e Salute Endocrina della Donna, AOU Policlinico G. Martino, Messina, ItalyDipartimento di Medicina Clinica e Sperimentale, Università di Messina, Messina, ItalyIstituto Auxologico Italiano, Verbania, ItalyMedico di Medicina Generale, ASP 5, Messina, ItalyMedico di Medicina Generale, ASP 5, Messina, ItalyMedico di Medicina Generale, ASP 5, Messina, ItalyMedico di Medicina Generale, ASP 5, Messina, ItalyMedico di Medicina Generale, ASP 5, Messina, ItalyMedico di Medicina Generale, ASP 5, Messina, ItalyMedico di Medicina Generale, ASP 5, Messina, ItalySocietà Italiana di Medicina Generale, Firenze, ItalyBiologo Nutrizionista, Endocrinologia dell’Infanzia, dell’Adolescenza e della Donna, Università di Messina, ItalyDipartimento di Medicina Clinica e Sperimentale, Università di Messina, Messina, Italy; Corresponding author at: Department of Clinical and Experimental Medicine, University Hospital of Messina, Via C. Valeria, 98125 Messina, Italy.Medico di Medicina Generale, ASP 5, Messina, ItalyObjective: Cross-sectional studies have reported that TSH above or close to the upper normal limit correlates with unfavorable metabolic and cardiovascular outcomes. Certain medications impair intestinal absorption of levothyroxine (L-T4), resulting in undertreated hypothyroidism (viz. failure of serum TSH to reach target levels, if hypothyroidism is primary).Further to evaluating the magnitude of sub-optimally treated primary hypothyroidism as a result of co-ingestion of those medications, we wished to ascertain whether the above complications would occur during a low number of years under polypharmacy. Method: In this retrospective study in collaboration with 8 family physicians, we enrolled adults with primary hypothyroidism under L-T4 therapy that, for 2 years minimum, was not associated with those medications (non-exposure, baseline) and that, for another 2 years minimum, it was (exposure). Outcomes were serum levels and proportions of serum TSH levels >4.12 mU/L, and proportions of complications. Complications were aggravation of pre-existing or de novo onset of any of metabolic syndrome, impaired fasting glycemia (IFG), diabetes mellitus, dyslipidemia, hypertension, coronary heart disease (CHD), cerebrovascular disease (CVD). Result: A total of 114 patients were enrolled. Duration of exposure to the interfering medication was 32.1 ± 6.9 months (median 31; range 24–55). Compared with non-exposure, the exposure period resulted in greater TSH levels (2.81 ± 3.62 [median 1.79] vs 1.27 ± 1.34 [median 0.93], P = 2.2 × 10−20) and proportions of values >4.12 mU/L (18.5% vs 4.7%, P = 1.2 × 10−7). Seventy-six patients (67%) had complications, whose rates of TSH >4.12 mU/L were greater than in the 36 complication-free patients (22% vs 11%, P = 0.018). Conclusion: During a median period of 31 months, there are relevant consequences for L-T4 treated adult hypothyroid patients resulting from hyperthyrotropinemia caused by medications impairing L-T4 absorption. This should be taken into account by future guidelines on hypothyroidism management. Keywords: Subclinical hypothyroidism, Levothyroxine malabsorption, Diabetes mellitus, Dyslipidemia, Hypertension, Cardiovascular diseaseshttp://www.sciencedirect.com/science/article/pii/S2214623719300237 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Salvatore Benvenga Rachele Pantano Giovanna Saraceno Luigi Lipari Antonio Alibrando Santi Inferrera Giuseppe Pantano Giuseppe Simone Sebastiano Tamà Riccardo Scoglio Maria Giovanna Ursino Carmen Simone Antonino Catalano Umberto Alecci |
spellingShingle |
Salvatore Benvenga Rachele Pantano Giovanna Saraceno Luigi Lipari Antonio Alibrando Santi Inferrera Giuseppe Pantano Giuseppe Simone Sebastiano Tamà Riccardo Scoglio Maria Giovanna Ursino Carmen Simone Antonino Catalano Umberto Alecci A minimum of two years of undertreated primary hypothyroidism, as a result of drug-induced malabsorption of l-thyroxine, may have metabolic and cardiovascular consequences Journal of Clinical & Translational Endocrinology |
author_facet |
Salvatore Benvenga Rachele Pantano Giovanna Saraceno Luigi Lipari Antonio Alibrando Santi Inferrera Giuseppe Pantano Giuseppe Simone Sebastiano Tamà Riccardo Scoglio Maria Giovanna Ursino Carmen Simone Antonino Catalano Umberto Alecci |
author_sort |
Salvatore Benvenga |
title |
A minimum of two years of undertreated primary hypothyroidism, as a result of drug-induced malabsorption of l-thyroxine, may have metabolic and cardiovascular consequences |
title_short |
A minimum of two years of undertreated primary hypothyroidism, as a result of drug-induced malabsorption of l-thyroxine, may have metabolic and cardiovascular consequences |
title_full |
A minimum of two years of undertreated primary hypothyroidism, as a result of drug-induced malabsorption of l-thyroxine, may have metabolic and cardiovascular consequences |
title_fullStr |
A minimum of two years of undertreated primary hypothyroidism, as a result of drug-induced malabsorption of l-thyroxine, may have metabolic and cardiovascular consequences |
title_full_unstemmed |
A minimum of two years of undertreated primary hypothyroidism, as a result of drug-induced malabsorption of l-thyroxine, may have metabolic and cardiovascular consequences |
title_sort |
minimum of two years of undertreated primary hypothyroidism, as a result of drug-induced malabsorption of l-thyroxine, may have metabolic and cardiovascular consequences |
publisher |
Elsevier |
series |
Journal of Clinical & Translational Endocrinology |
issn |
2214-6237 |
publishDate |
2019-06-01 |
description |
Objective: Cross-sectional studies have reported that TSH above or close to the upper normal limit correlates with unfavorable metabolic and cardiovascular outcomes. Certain medications impair intestinal absorption of levothyroxine (L-T4), resulting in undertreated hypothyroidism (viz. failure of serum TSH to reach target levels, if hypothyroidism is primary).Further to evaluating the magnitude of sub-optimally treated primary hypothyroidism as a result of co-ingestion of those medications, we wished to ascertain whether the above complications would occur during a low number of years under polypharmacy. Method: In this retrospective study in collaboration with 8 family physicians, we enrolled adults with primary hypothyroidism under L-T4 therapy that, for 2 years minimum, was not associated with those medications (non-exposure, baseline) and that, for another 2 years minimum, it was (exposure). Outcomes were serum levels and proportions of serum TSH levels >4.12 mU/L, and proportions of complications. Complications were aggravation of pre-existing or de novo onset of any of metabolic syndrome, impaired fasting glycemia (IFG), diabetes mellitus, dyslipidemia, hypertension, coronary heart disease (CHD), cerebrovascular disease (CVD). Result: A total of 114 patients were enrolled. Duration of exposure to the interfering medication was 32.1 ± 6.9 months (median 31; range 24–55). Compared with non-exposure, the exposure period resulted in greater TSH levels (2.81 ± 3.62 [median 1.79] vs 1.27 ± 1.34 [median 0.93], P = 2.2 × 10−20) and proportions of values >4.12 mU/L (18.5% vs 4.7%, P = 1.2 × 10−7). Seventy-six patients (67%) had complications, whose rates of TSH >4.12 mU/L were greater than in the 36 complication-free patients (22% vs 11%, P = 0.018). Conclusion: During a median period of 31 months, there are relevant consequences for L-T4 treated adult hypothyroid patients resulting from hyperthyrotropinemia caused by medications impairing L-T4 absorption. This should be taken into account by future guidelines on hypothyroidism management. Keywords: Subclinical hypothyroidism, Levothyroxine malabsorption, Diabetes mellitus, Dyslipidemia, Hypertension, Cardiovascular diseases |
url |
http://www.sciencedirect.com/science/article/pii/S2214623719300237 |
work_keys_str_mv |
AT salvatorebenvenga aminimumoftwoyearsofundertreatedprimaryhypothyroidismasaresultofdruginducedmalabsorptionoflthyroxinemayhavemetabolicandcardiovascularconsequences AT rachelepantano aminimumoftwoyearsofundertreatedprimaryhypothyroidismasaresultofdruginducedmalabsorptionoflthyroxinemayhavemetabolicandcardiovascularconsequences AT giovannasaraceno aminimumoftwoyearsofundertreatedprimaryhypothyroidismasaresultofdruginducedmalabsorptionoflthyroxinemayhavemetabolicandcardiovascularconsequences AT luigilipari aminimumoftwoyearsofundertreatedprimaryhypothyroidismasaresultofdruginducedmalabsorptionoflthyroxinemayhavemetabolicandcardiovascularconsequences AT antonioalibrando aminimumoftwoyearsofundertreatedprimaryhypothyroidismasaresultofdruginducedmalabsorptionoflthyroxinemayhavemetabolicandcardiovascularconsequences AT santiinferrera aminimumoftwoyearsofundertreatedprimaryhypothyroidismasaresultofdruginducedmalabsorptionoflthyroxinemayhavemetabolicandcardiovascularconsequences AT giuseppepantano aminimumoftwoyearsofundertreatedprimaryhypothyroidismasaresultofdruginducedmalabsorptionoflthyroxinemayhavemetabolicandcardiovascularconsequences AT giuseppesimone aminimumoftwoyearsofundertreatedprimaryhypothyroidismasaresultofdruginducedmalabsorptionoflthyroxinemayhavemetabolicandcardiovascularconsequences AT sebastianotama aminimumoftwoyearsofundertreatedprimaryhypothyroidismasaresultofdruginducedmalabsorptionoflthyroxinemayhavemetabolicandcardiovascularconsequences AT riccardoscoglio aminimumoftwoyearsofundertreatedprimaryhypothyroidismasaresultofdruginducedmalabsorptionoflthyroxinemayhavemetabolicandcardiovascularconsequences AT mariagiovannaursino aminimumoftwoyearsofundertreatedprimaryhypothyroidismasaresultofdruginducedmalabsorptionoflthyroxinemayhavemetabolicandcardiovascularconsequences AT carmensimone aminimumoftwoyearsofundertreatedprimaryhypothyroidismasaresultofdruginducedmalabsorptionoflthyroxinemayhavemetabolicandcardiovascularconsequences AT antoninocatalano aminimumoftwoyearsofundertreatedprimaryhypothyroidismasaresultofdruginducedmalabsorptionoflthyroxinemayhavemetabolicandcardiovascularconsequences AT umbertoalecci aminimumoftwoyearsofundertreatedprimaryhypothyroidismasaresultofdruginducedmalabsorptionoflthyroxinemayhavemetabolicandcardiovascularconsequences AT salvatorebenvenga minimumoftwoyearsofundertreatedprimaryhypothyroidismasaresultofdruginducedmalabsorptionoflthyroxinemayhavemetabolicandcardiovascularconsequences AT rachelepantano minimumoftwoyearsofundertreatedprimaryhypothyroidismasaresultofdruginducedmalabsorptionoflthyroxinemayhavemetabolicandcardiovascularconsequences AT giovannasaraceno minimumoftwoyearsofundertreatedprimaryhypothyroidismasaresultofdruginducedmalabsorptionoflthyroxinemayhavemetabolicandcardiovascularconsequences AT luigilipari minimumoftwoyearsofundertreatedprimaryhypothyroidismasaresultofdruginducedmalabsorptionoflthyroxinemayhavemetabolicandcardiovascularconsequences AT antonioalibrando minimumoftwoyearsofundertreatedprimaryhypothyroidismasaresultofdruginducedmalabsorptionoflthyroxinemayhavemetabolicandcardiovascularconsequences AT santiinferrera minimumoftwoyearsofundertreatedprimaryhypothyroidismasaresultofdruginducedmalabsorptionoflthyroxinemayhavemetabolicandcardiovascularconsequences AT giuseppepantano minimumoftwoyearsofundertreatedprimaryhypothyroidismasaresultofdruginducedmalabsorptionoflthyroxinemayhavemetabolicandcardiovascularconsequences AT giuseppesimone minimumoftwoyearsofundertreatedprimaryhypothyroidismasaresultofdruginducedmalabsorptionoflthyroxinemayhavemetabolicandcardiovascularconsequences AT sebastianotama minimumoftwoyearsofundertreatedprimaryhypothyroidismasaresultofdruginducedmalabsorptionoflthyroxinemayhavemetabolicandcardiovascularconsequences AT riccardoscoglio minimumoftwoyearsofundertreatedprimaryhypothyroidismasaresultofdruginducedmalabsorptionoflthyroxinemayhavemetabolicandcardiovascularconsequences AT mariagiovannaursino minimumoftwoyearsofundertreatedprimaryhypothyroidismasaresultofdruginducedmalabsorptionoflthyroxinemayhavemetabolicandcardiovascularconsequences AT carmensimone minimumoftwoyearsofundertreatedprimaryhypothyroidismasaresultofdruginducedmalabsorptionoflthyroxinemayhavemetabolicandcardiovascularconsequences AT antoninocatalano minimumoftwoyearsofundertreatedprimaryhypothyroidismasaresultofdruginducedmalabsorptionoflthyroxinemayhavemetabolicandcardiovascularconsequences AT umbertoalecci minimumoftwoyearsofundertreatedprimaryhypothyroidismasaresultofdruginducedmalabsorptionoflthyroxinemayhavemetabolicandcardiovascularconsequences |
_version_ |
1725462455907254272 |